Nuvo Research Inc Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: DaveAu who wrote (13602)	9/16/2004 11:40:21 AM
From: Cal Gary	of 14101

... and more media coverage! Globe says Dimethaid touts future of Pennsaid 2004-09-16 05:57 ET - In the News The Globe and Mail reports in its Thursday, Sept. 16, edition that fighting to score points with shareholders ahead of a proxy vote on Tuesday, Dimethaid Research predicted that sales of its Pennsaid pain ointment will top $1.5-million (U.S.) for the first quarter ended Aug. 31, a year-over-year increase of 120 per cent. The Globe's Leonard Zehr writes that Dimethaid also forecast continued growth in worldwide sales this year, noting that it plans to begin shipping Pennsaid to its Portuguese partner in late September, with a marketing campaign in Greece scheduled to start later in the fiscal year. Despite earlier warnings that it would run out of money this summer, Dimethaid said it ended the quarter with $654,000 (U.S.) in cash. "Once we get through this period of uncertainty, we can resolve the financial situation and move ahead with our business plan," said president and chief executive officer Rebecca Keeler. Dimethaid's shares fell two Canadian cents to conclude Wednesday's trading session on the Toronto Stock Exchange at 47 Canadian cents. The stock has a 52-week trading range of $1.99 (Canadian) to 25 Canadian cents.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next